Press

Small Pharma Announces SPL028 R&D Strategy Update

Jul 5 • 4 min read

Small Pharma Inc. (TSXV: DMT / OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce a research and development (R&D) strategy update, aimed at expediting its clinical program of SPL028, the Company’s novel deuterated N, N-dimethyltryptamine (“DMT”) compound with multi-layered intellectual property (“IP”) protection. SPL028 is…

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Jul 5 • 3 min read

Wesana Health Holdings Inc. (CSE:WESA / OTCQB:WSNAF), today announced the successful closing of the sale by Wesana Health Inc. (“WHI”), a subsidiary of the Company, of WHI’s right and interest in the SANA-013 intellectual property and development related assets pursuant to the terms of the asset purchase agreement with Lucy Scientific Discovery Inc. (NASDAQ:LSDI) (“Lucy”)…

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

Jul 3 • 4 min read

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced today the results of its annual general and special meeting of shareholders (“ AGSM ”), held online and in virtual-only format…

Cybin to Participate in PSYCH Symposium London 2023

Jun 30 • 2 min read

-Cybin Inc. (NEO:CYBN / NYSE American:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin’s Chief Medical Officer, will be participating in the upcoming PSYCH Symposium 2023 taking place Thursday, July 6, 2023 at the British…

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer

Jun 30 • 3 min read

Cybin Inc. (NEO:CYBN / NYSE American:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the appointment of Aaron Bartlone as Chief Operating Officer of Cybin Inc., effective July 1, 2023. Mr. Bartlone has served as Chief Operating Officer of Cybin’s U.S. subsidiary, Cybin…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435